In situ antigen-capture strategies for enhancing dendritic cell-mediated anti-tumor immunity

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Dendritic cell (DC)-mediated immunotherapy shows promise for cancer treatment by linking tumor antigens to anti-tumor immune responses.
• The tumor microenvironment (TME) often suppresses DC function, hindering antigen uptake, maturation, and migration, leading to immune tolerance.
• Existing strategies struggle to overcome TME-induced immunosuppression, limiting effective anti-tumor immunity.

Purpose of the Study:

• To review the impact of the TME on DC functionality and explore in situ antigen-capturing nanovaccines (AC-NVs) as a solution.
• To detail the mechanisms of AC-NVs, including various antigen capture methods.
• To discuss recent advancements in AC-NVs, their material properties, and their role in enhancing anti-tumor immunity.

Main Methods:

• Review of literature on TME effects on DCs.
• Analysis of mechanisms of in situ antigen capture by nanovaccines (covalent, noncovalent, combined).
• Survey of biomaterials used in AC-NVs and their functional properties.

Main Results:

• The TME imposes significant immunosuppressive barriers on DC function, including impaired antigen uptake.
• AC-NVs employ diverse strategies for efficient antigen capture and DC functionalization.
• Various biomaterials are being utilized to construct AC-NVs with tailored properties for enhanced anti-tumor immunity.

Conclusions:

• AC-NVs offer a promising approach to overcome TME-mediated immunosuppression and restore DC-driven anti-tumor immunity.
• These nanovaccines hold potential for personalized cancer vaccine development and clinical translation.
• Further research is needed to optimize AC-NVs for maximizing immune responses and clinical efficacy.